Allogene Therapeutics, Inc. (ALLO) | Investment Case

1. Company Snapshot

1.a. Company Description

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma.

In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors.The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc.It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates.

The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Show Full description

1.b. Last Insights on ALLO

Allogene Therapeutics' recent performance was impacted by the passing of founding board member David Bonderman in December 2024, which may have led to a temporary disruption in the company's operations. Additionally, the company's financial health is stable, with a cash runway until Q1 2026, as mentioned in a February 2025 report. However, the recent IND clearance for ALLO-329 in January 2025, advancing its next-generation allogeneic CAR T into autoimmune diseases, is a promising development for the company's pipeline.

1.c. Company Highlights

Last Price	2.38
Change Percentage	9.45%
Open	2.23
Previous Close	2.17
Market Cap ( Millions)	579
Volume	10728319
Year High	4.46
Year Low	0.86
M A 50	2.3
M A 200	1.55

FCF Yield	-25.84%
Dividend Yield	0.00%
ROE	-57.07%
Debt / Equity	28.46%
Net Debt / EBIDTA	-17.40%
Price To Book	1.79
Price Earnings Ratio	-2.74
Price To FCF	-3.87
Price To sales	0
EV / EBITDA	-3.37

2. Allogene Therapeutics: Milestones Ahead, Cash in Hand

Allogene Therapeutics reported a Q4 2025 net loss of $38.8 million ($0.17 EPS)<sup>1</sup>, while sustaining a $258.3 million cash balance that extends its runway into 2028. R&D spending reached $28.6 million this quarter and $150.2 million for the full year, underscoring the company’s commitment to advancing high‑impact programs amid disciplined capital stewardship.

Publication Date: Apr -13

                                    📋 Highlights
                                    Cash Runway Extended:
                                                Allogene holds $258.3M in cash, extending its runway into 2028.
R&D Expenditure:
                                                Full-year 2025 R&D costs reached $150.2M, with Q4 expenses at $28.6M.
2026 Financial Guidance:
                                                Operating cash expenses projected at $150M, with GAAP operating expenses at $210M.
ALPHA-3 MRD Clearance Goal:
                                                Aims for 25-30% absolute improvement in MRD clearance to alter disease outcomes in lymphoma.
Spontaneous MRD Conversion Baseline:
                                                Observation arm expects 20% spontaneous MRD conversion (~2-3 patients in 12-patient arm).

                                

Financial Performance and Cash Position

The $38.8 million loss and $0.17 EPS reflect the continued investment in research and development, yet the firm’s liquidity remains robust. With cash reserves covering projected 2026 operating expenses of roughly $210 million, the company maintains financial flexibility to pursue pivotal clinical milestones without immediate refinancing pressure.

Clinical Milestones: ALPHA‑3 and SemiCell

ALPHA‑3, a randomized trial in large B‑cell lymphoma, is designed to evaluate early MRD‑guided consolidation using allogeneic CAR‑T. The study aims for a 25‑30% absolute improvement in MRD clearance, potentially reshaping cure rates. SemiCell has demonstrated consistent efficacy across risk spectrums, bolstering confidence in the platform’s scalability and deliverability.

ALLO‑329 Proof‑of‑Concept Outlook

Allogene anticipates delivering proof‑of‑concept data for ALLO‑329 in June 2026, with a subsequent update slated for year‑end. This data will be critical in validating the platform’s therapeutic value in autoimmune disease and earlier‑line oncology, setting the stage for broader clinical development.

Guidance and Capital Management

Operating cash expense guidance for 2026 is projected at approximately $150 million, with GAAP operating expenses around $210 million. The firm’s strategy focuses on disciplined execution, targeting data that define allogeneic CAR‑T’s role in frontline therapy while preserving capital for long‑term growth.

Valuation Snapshot

At present, Allogene trades at a P/E of –3.14 and a P/B of 2.05, reflecting the market’s anticipation of future upside despite current losses. Negative ROIC and ROE metrics underscore the investment‑heavy nature of the business, yet the strong cash position positions the company to capitalize on emerging therapeutic opportunities.

3. NewsRoom

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Apr -15

Source: globenewswire.com

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

Apr -15

Source: globenewswire.com

ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study

Apr -14

Source: zacks.com

Traders Purchase High Volume of Allogene Therapeutics Call Options (NASDAQ:ALLO)

Apr -14

Source: defenseworld.net

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

Apr -13

Source: globenewswire.com

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript

Apr -13

Source: seekingalpha.com

Allogene: Early ALPHA3 Data Suggests Potential Paradigm Shift For Cema-Cel In LBCL

Apr -13

Source: seekingalpha.com

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

Apr -13

Source: businesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Allogeneic T Cell Therapies

Expected Growth: 25.4%

Growing demand for cancer treatment, increasing adoption of gene-modified T cell therapies, and Allogene Therapeutics' innovative off-the-shelf approach are expected to drive the growth of allogeneic T cell therapies.

7. Detailed Products

ALLO-501

ALLO-501 is an allogenic T cell therapy that targets CD19, a protein expressed on the surface of certain B cells, for the treatment of relapsed or refractory non-Hodgkin lymphoma.

ALLO-501A

ALLO-501A is an allogenic T cell therapy that targets CD19, a protein expressed on the surface of certain B cells, for the treatment of relapsed or refractory large B cell lymphoma.

ALLO-715

ALLO-715 is an allogenic T cell therapy that targets BCMA, a protein expressed on the surface of certain multiple myeloma cells, for the treatment of relapsed or refractory multiple myeloma.

ALLO-605

ALLO-605 is an allogenic T cell therapy that targets FLT3, a protein expressed on the surface of certain acute myeloid leukemia cells, for the treatment of relapsed or refractory acute myeloid leukemia.

8. Allogene Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Allogene Therapeutics, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to ongoing research and development in the field of gene therapy.

Bargaining Power Of Customers

Allogene Therapeutics, Inc. has a diverse customer base, but the bargaining power of customers is limited due to the specialized nature of its products and services.

Bargaining Power Of Suppliers

Allogene Therapeutics, Inc. relies on a few key suppliers for raw materials and services, which gives them some bargaining power, but the company's strong relationships and contracts mitigate this risk.

Threat Of New Entrants

The gene therapy market is rapidly evolving, and new entrants are likely to emerge, posing a significant threat to Allogene Therapeutics, Inc.'s market share and competitive position.

Intensity Of Rivalry

The gene therapy market is highly competitive, with several established players and new entrants vying for market share, leading to a high intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	15.66%
Debt Cost	3.95%
Equity Weight	84.34%
Equity Cost	8.46%
WACC	7.75%
Leverage	18.57%

11. Quality Control: Allogene Therapeutics, Inc. passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

OncoCyte

A-Score: 4.7/10

Value: 7.1

Growth: 5.9

Quality: 3.1

Yield: 0.0

Momentum: 8.0

Volatility: 4.3

1-Year Total Return ->

Kezar Life Sciences

A-Score: 3.7/10

Value: 8.0

Growth: 5.6

Quality: 4.2

Yield: 0.0

Momentum: 3.0

Volatility: 1.3

1-Year Total Return ->

Biomea Fusion

A-Score: 3.3/10

Value: 6.9

Growth: 3.4

Quality: 4.1

Yield: 0.0

Momentum: 5.0

Volatility: 0.3

1-Year Total Return ->

Allogene Therapeutics

A-Score: 3.0/10

Value: 7.6

Growth: 4.3

Quality: 4.2

Yield: 0.0

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

Pliant Therapeutics

A-Score: 2.6/10

Value: 8.0

Growth: 3.1

Quality: 3.5

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

Maravai LifeSciences

A-Score: 2.5/10

Value: 7.1

Growth: 2.1

Quality: 3.9

Yield: 0.0

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

16.34%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

7.75%

Allogene Therapeutics, Inc. - US0197701065

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on ALLO

1.c. Company Highlights

Stable Momentum

Average Quality

Average Growth

Revenues Beats

Medium Volatility

Weak Momentum

Earnings Beats

Better Quality

Cheaper

Fairly Valued

2. Allogene Therapeutics: Milestones Ahead, Cash in Hand

Financial Performance and Cash Position

Clinical Milestones: ALPHA‑3 and SemiCell

ALLO‑329 Proof‑of‑Concept Outlook

Guidance and Capital Management

Valuation Snapshot

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Allogeneic T Cell Therapies

Expected Growth: 25.4%

7. Detailed Products

ALLO-501

ALLO-501A

ALLO-715

ALLO-605

8. Allogene Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Allogene Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

2.37$

Current Price

2.37$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA